



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number:

0 220 760 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: 21.08.91 (51) Int. Cl.⁵: **A61K 9/18, A61K 47/00, A61K 31/44**
- (21) Application number: **86201704.3**
- (22) Date of filing: **02.10.86**

- (54) Process for the preparation of solid nifedipine formulations of high bioavailability and with sustained effect, and formulations thus obtained.

- (30) Priority: 15.10.85 IT 2249485
- (43) Date of publication of application: 06.05.87 Bulletin 87/19
- (45) Publication of the grant of the patent: 21.08.91 Bulletin 91/34
- (84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE
- (56) References cited:
- | | |
|-----------------|-----------------|
| EP-A- 0 001 247 | EP-A- 0 182 007 |
| DE-A- 2 822 882 | FR-A- 2 256 765 |
| GB-A- 2 053 681 | GB-A- 2 160 100 |

CHEMICAL ABSTRACTS, vol. 99, 1983, pages 344-345, abstract no. 164018g, Columbus, Ohio, US; & JP-A-58 116 414 (YAMANOUCHI PHARMACEUTICAL CO. LTD) 11-07-1983

- (73) Proprietor: **EURAND ITALIA S.p.A.**
Via Privata Pasteur 1
I-20092 Cinisello Balsamo, Milano(IT)
- (72) Inventor: **Calanchi, Massimo**
Via Catalafimi 12
I-20052 Monza Milano(IT)
Inventor: **Rossi, Piergiorgio**
Via Pecorini 16
I-20138 Milano(IT)
- (74) Representative: **Riccardi, Sergio**
Riccardi & Co. Via Macedonio Melloni, 32
I-20129 Milano(IT)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

The present invention relates to a process allowing to increase the bioavailability of Nifedipine and its derivatives with respect to other solid oral forms. This process consists in coprecipitating Nifedipine and polyethylene glycol from a solution, into a very high surface obtained by means of the micronization of an inert excipient soluble in the gastrointestinal juices or in precipitating polyethylene glycol on a homogeneous mixture of Nifedipine and an inert excipient, both being micronized.

Due to the low solubility and the high sensitivity to light, Nifedipine presents notable drawbacks in the preparation of stable and bioavailable forms. Nowadays nifedipine is mostly administered in a suspensions of liquid excipients, consisting essentially of propylene and polyethylene glycols. In the forms of soft gelatine capsules. Instead, the solid oral forms, tablets, sugar-coated pills, hard gelatine capsules, are absorbed very slowly and consequently are used as retard compositions. However, these are characterized by a bioavailability distinctly inferior to that of the rapid formulations: generally between 40 and 80%. The scarce absorption and the low bioavailability of crystalline nifedipine administered orally is made evident in the articles of I. Sugitomo et al. published on Drug Development and Industrial Pharmacy, 6 (2), 137-160 (1980), and Chem. Pharm. Bull. 29 (6), 1715-1723 (1981).

In order to increase the bioavailability of nifedipine, different techniques have been tried, namely, for example, the transformation of the crystals into fine powder, the transformation from the crystalline to the amorphous form, the formation of clathrates or compounds of inclusion with betacyclodextrines, the formation of solid solutions with polyethylene glycols, the formation of co-precipitates with polyvinylpyrrolidone.

U.K. patent specification GB-2139892 discloses the preparation of tablets containing nifedipine partially in the form of ground crystals, so as to reduce the dimension between 1 and 10 microns, partially in the form of co-precipitate with polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose or hydroxypropylcellulose.

In Canadian patent specification CA-1180277, the improvement of the bioavailability of nifedipine is obtained by grinding the active substance so as to obtain a specific surface between 0.5 and 6 m²/g, and mixing with excipients suitable for the preparation of the desired solid active-substance forms, namely, capsules, tablets, pills, sugar-coated pills or suppositories.

In U.K. patent specification GB-1456618, the aim is achieved by making a solution of nifedipine in polyethylene glycol of a molecular weight of 200 - 400 in the presence of a surfactant, and absorbing said solution on a sufficient quantity of one or more inert excipients, soluble or insoluble in the gastrointestinal juices, by simply transforming the product into a powder and being able to make tablets out of it. That is, the known property of the polyethylene glycols in giving solid solutions is exploited.

In German patent specification DE-2822882, cases are claimed wherein nifedipine is simply mixed with excipients such as polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, aminoacids, and others, alone or in the presence of surfactants and/or calcium lactate and inert excipients, and cases are claimed wherein nifedipine is co-precipitated on inert excipients from solutions with polyvinylpyrrolidone, with the other substances mentioned hereinbefore, alone or in the presence of surfactants and/or calcium lactate; In Example 20 coprecipitation of nifedipine and polyethylene glycol on inert excipients is disclosed, but using polyethylene glycol of low molecular weight (400). No importance is attached to the physical-chemical characteristics of the substances mixed with nifedipine, that are just a list of excipients used to granulate and to facilitate the bioavailability of water insoluble drugs. No care is made to the size of the drug and the excipients.

Also the process, subject of the present invention, relates to the preparation of solid forms of dosage of nifedipine or its derivatives, but it differs substantially from those previously cited. According to the present invention, in fact, a solution of nifedipine and polyethylene glycol of high molecular weight between 2000 and 6000 is made in a common solvent (or mixture of solvents) and the solution is dispersed on a micronized inert excipient which is soluble in the gastrointestinal juices. The characterizing features of the formulation and of the process are recited in Claim 1 and Claim 9, respectively.

Nifedipine is thus obtained with a very small particle size distribution by micronization or by the coprecipitation from an organic solution of the drug and the high molecular weight polyethylene glycol on a water soluble inert excipient; moreover, it is essential to use in the mixture the high molecular weight polyethylene glycol because it has the property to homogeneously distribute the drug on the inert support that has to be water soluble and micronized. Lastly, the hydroxypropylmethylcellulose is used in the present invention only when it is desired to obtain a sustained release of the drug.

According to the present invention, the micronizing powders are in the form of very fine particles having an extremely high total specific surface, as they are obtained by a granulation step through an INOX ASTM N° 25 stainless steel wire mesh with openings of 0.71 mm, possibly after one or more pregranulation steps

through a larger ASTM N° 8 screen with openings of 2.38 mm to speed up to process.

The surfactant property of the polyethylene glycol of high molecular weight is therefore exploited so as to be able to "wet" the microparticles of the inert excipient with the solution, and spread it over all of the very high surface available so that, when the solvent evaporates, the nifedipine crystals which precipitate are tiny and remain as such due to the impossibility of swelling or aggregation between each other. It was also noted that it is possible to micronize Nifedipine, mixing it with the micronized inert excipient and then "wet" such a mixture with a polyethylene glycol solution. When the solvent evaporates, polyethylene glycol precipitates in very fine particles and in intimate contact with the Nifedipine particles. In both cases one obtains a granulate of Nifedipine and polyethylene glycol finely and homogeneously dispersed in the micronized inert excipient, thus having the same characteristics. It is important, moreover, that the inert excipient is easily soluble in the gastrointestinal juices so as to leave the nifedipine microcrystals free after swallowing.

The obtained granulate is finally mixed with the excipients suitable to the manufacture of the desired solid forms of dosage: preferably tablets, but also sugar-coated pills, lozenges and suppositories. Testing the bioavailability, it was surprisingly found that these tablets have the characteristics of a retard product and have a bioavailability equivalent to 100% of the oral forms on the market, wherein the active substance is in liquid suspension in soft gelatine capsules.

In the process specified in the present invention, polyethylene glycols with a molecular weight exceeding 2000, and preferably between 5000 and 6000, are used. The ratio between active substance and polyethylene glycol may vary in the interval between 20:80 and 80:20, and preferably 40:60 and 60:40.

Nifedipine and polyethylene glycol may be dissolved in a common solvent and successively this is evaporated to obtain the co-precipitate. Preferably, however, the solution is mixed, for example in a kneader, with a micronized inert excipient which is very soluble in the gastrointestinal juices, obtaining a granulate which is successively dried. In this phase, the co-precipitation of the active substance with the polyethylene glycol in intimate mixture with the inert excipient, is obtained. As already mentioned, alternatively one may add in the kneader a polyethylene glycol solution to a homogeneous mixture of Nifedipine and inert excipient, where both Nifedipine and excipient are micronized. Illustrative but non-limiting examples of the said micronized inert excipients are cited: sucrose, lactose, glucose, fructose, levulose, mannitol, sorbitol, glycerol, xylitol, pentaerythritol, maltodextrine. The ratio between co-precipitate and inert excipient may vary in a very broad range, but for technical-economical reasons, that preferred is between 1:20 and 1:4.

The granulate of active substance, polyethylene and micronized inert excipient may be used directly for the preparation of tablets, preferably adding a lubricant agent.

It was also found that a further prolongation of the retardant effect can be obtained if substances which, when in contact with the gastrointestinal juices, swell again and successively dissolve themselves slowly such as, for instance, illustrative and non-limiting examples: hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose, carboxyvinyl polymers, xanthan gum, in quantities variable between 5% and 50% of the tablet weight are preferably between 10 and 30%, are added to the granulate prepared in the manners hereinbefore specified.

For the first time, the prolongation of the retardant effect consents a single daily administration, without reducing the bioavailability and therefore the efficiency of the active substance; in such a way, a greater compliance on the part of the patient is also obtained, which is an important factor in long-term therapies.

The following examples serve to better illustrate the present invention:

45 EXAMPLE 1

Three solutions having the composition illustrated in the following table:

50

55

EP 0 220 760 B1

Components	Solution I g	Solution II g	Solution III g
Nifedipine	110	100	90
Polyethylene glycol (PEG 6000)	110	100	90
Acetone	1010	920	830
Deionized water	190	170	150

are prepared in the manner which is now specified:

Nifedipine is dissolved in acetone and PEG in water, using a suitable vessel equipped with stirrer.

The nifedipine acetonetic solution and the aqueous PEG 6000 solution are then mixed in such a way so as to obtain the solutions indicated in the table. 3.9 kg of micronized lactose (90% inferior to 15 microns) are placed in a kneader with horizontal blades, to which 1.42 kg of solution I is added.

When the solution is homogeneously distributed, the mixture is transferred to a stove with forced air circulation where it is dessicated at 45° C for 2 hours. It is granulated with an oscillating granulator provided with a Inox ASTM N° 8 stainless steel metal wire mesh (opening 2.38 mm) and dessication is completed.

The evaporation of the solvent causes the co-precipitation of the active substance and polyethylene glycol in fine form and homogeneously dispersed in the inert excipient.

The granulate thus obtained is ground so as to be able to proceed with the subsequent application of the active substance and polyethylene glycol solution.

Afterwards, the operations specified hereinbefore are repeated with solution II and then with solution III. After the last blending, the dried product is granulated through a inox ASTM N° 25 stainless steel wire mesh (openings of the mesh 0.71 mm) in order to obtain micronized granules in the form of very small particles as hereinbefore defined.

In all the examples given in this disclosure, ASTM N°25 wire mesh (opening 0.71 mm) could be used for all passages through the oscillating granulator, but it is preferred to use the larger screen of ASTM N°8 (opening 2.38 mm) in the first passages just to speed up the process.

The tablets are then prepared. For this purpose, 4.5 kg of granulate and 75 g of magnesium stearate are mixed for 15 min. in a cubic mixer.

A chromed punch with a capsular shape having a 15 mm length, a 6 mm width and a 5 mm bending radius, is used for the preparation of the tablets. Tablets having the following characteristics are obtained:

Nifedipine content : 20 mg

Theoretical weight : 305 mg

Hardness (determined with Erweka TBH 28 apparatus) : 8 - 10 kg

Friability (measured with Roche friabilometer, by rotating 10 tablets for 4 min. and determining the loss of weight) : inferior to 1%

EXAMPLE 2

Two solutions are prepared, having the compositions illustrated in the following table:

EP 0 220 760 B1

	Composition	Solution I	Solution II
5	Nifedipine	220 g	180 g
	PEG 6000	220 g	180 g
10	Methylene chloride	3170 g	2650 g

operating with the following method:

15 Nifedipine and methylene chloride are placed in a suitable vessel equipped with stirrer, and stirred until complete dissolution. Polyethylene glycol is added and stirred until complete dissolution.

5.2 kg of micronized mannitol is placed in a kneader and mixed with 3.610 kg of solution added by pouring thinly in about 2 min. When adding of the solution is terminated, mixing continues for 4-5 min.

20 During the latter operation, it is suitable to operate with a strong suction through the kneader lid to facilitate the evaporation of the methylene chloride.

The mixture is distributed on the grid of a stove, in a thin layer, and is dried with a single circulation of air at room temperature for about 2 hours or, anyway, until the almost total elimination of the methylene chloride.

25 Then granulation is done with an oscillating granulator provided with a inox ASTM N° 8 stainless steel mesh. The granulate is again distributed on the same grid and is dried with air circulation at 45° C for over 2-3 hours.

After having ground the granulate, the operations are repeated using solution II operating with the same method.

30 After the last blending, the dried granulate must be granulated with the oscillating granulator provided with inox steel ASTM N° 25 wire mesh (opening 0.71 mm).

In a cubic mixer

60 kg of granulate

1 kg of stearate magnesium

8 kg of hydroxypropylmethylcellulosa (Methocel E 4 M)

35 are placed and mixed for 15 min.

A chromed capsule-shaped punch having 17.5 mm length, 7 mm width and 7 mm bending radius is used for the preparation of the tablets. Tablets having the following characteristics are thus obtained:

Nifedipine content : 40 mg

theoretic weight : 690 mg

40 hardness (determined as specified in example 1) : 8 - 10

friability (determined as specified in example 1) : inferior to 1%

EXAMPLE 3

45 In a suitable vessel equipped with stirrer 1100 g of deionized water are charged and 300 g PEG are dissolved in said water under agitation.

In a cube mixer 3900 g of micronized lactose (90% smaller than 4 microns) and 300 g of micronized nifedipine (with a total surface higher than 6 m²/g) are intimately mixed.

50 Such a mixture is charged in a kneader with horizontal blades and is wetted with the PEG aqueous solution.

When the solution is homogeneously distributed, the mixture is transferred to a stove with forced air circulation where it is dried for 2 hours at 45° C.

Granulation is effected with an oscillating granulator provided with a inox ASTM N°8 stainless steel metal wire mesh (opening 2.38 mm) and dissication is completed.

55 Tablets are then prepared as described in Example 1.

EXAMPLE 4

EP 0 220 760 B1

In a cube mixer 5.2 kg of micronized mannitol and 400 g of micronized nifedipine (with a total surface higher than 6 m² /g) are intimately mixed.

The mixture is charged in a kneader with horizontal blades and is wetted with a solution of 400 g PEG dissolved in 5820 g of methylene chloride. When the addition of the solution is terminated, mixing is continued for 4-5 minutes. During the later operation it is suitable to operate with a strong suction through the kneader lid to facilitate the evaporation of methylene chloride.

The mixture is distributed on the grid of a stove, in a thin layer, and is dried with a single circulation of air at room temperature for about 2 hours or anyway until the almost total elimination of methylene chloride.

The dry granulate is granulated with an oscillating granulator provided with a inox ASTM N°8 stainless steel mesh (wire mesh opening 2.38 mm). Tablets are then prepared as described in Example 2.

EXAMPLE 5

The tablets prepared according to the specifications in the examples 1 and 2 are analysed according to the method specified in the American Pharmacopaea (USP), XX ed., pag. 1243 and following, Apparatus 2, at a temperature of 37° C and 125 r.p.m.

A tablet, having a dosage of 20 or 40 mg of active principle, is placed in 500 ml of acetic acid 5 N, at a temperature of 37° C, oscillating the blade at 125 r.p.m.

Samples are withdrawn after 15, 30, 45, 60, 75 minutes for the 20 mg tablets and after 1, 2, 4, 6, 8, 10 hours for the 40 mg tablets and the quantity of nifedipine passed in solution is determined with a spectrophotometric method. The following percentage values of active substance released by the tablets are found:

25	% of Nifedipine released after						
		15 min.	30 min.	45 min.	60 min.	75 min.	
30	Example 1	24	55	78	95	96	
	" 3	26	58	81	96	98	
35		1 hour	2 hours	4 hours	6 hours	8 hours	10 hours
	Example 2	10	20	42	62	81	100
	" 4	13	23	49	64	82	100

EXAMPLE 6

The formulation in 20 mg tablets underwent a bioavailability test on six adult subjects, healthy and of both sexes, in comparison with a conventional rapid release preparation and one with substaisted release, both in the market.

The experimental products were labelled as follows:

"A" = Adalat (Bayer), 10 mg capsule (conventional product for comparison)

"B" = Adalat AR (Bayer), 20 mg tablets (sustained release product for comparison)

"C" = Nifedipine Example 1, 20 mg tablets

The product "A" was administered in two successive doses of 10 mg each at zero time and at the sixth hour; the blood withdrawals for the determination of the blood plasmatic levels were effected after 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 14, 16, and 24 hours after swallowing of the first dose.

For the two preparations "B" and "C", instead, a single dose of 20 mg was administered and the blood withdrawals were done after 1, 2, 3, 4, 6, 9, 12 and 24 hours.

The average curves of the plasmatic levels obtained, are reported in the table 1 and graphically illustrated in Fig. 1.

The maximum concentrations (C_{max}), the relative appearance times (T_{max}) and the areas under the concentration-time curve (AUC) from zero to infinity, were calculated from the average curves. These were obtained from the total of the area comprised between zero and the last level (C_n), calculated with the trapeze method, plus the C_n/K_{el} portion, where C_n represents the last level and K_{el} is the elimination constant (λ) ($=0.185$) of the conventional product.

As an indication of the sustained release characteristics of the preparations, the average residence times of nifedipine in the plasma were calculated (mean residence time = MRT) according to the formula

$$MRT = \frac{AUMC_{00}}{AUC_{00}}$$

Wherein $AUMC_{00}$ is the area under the first moment of the curve and AUC_{00} is the conventional area under the curve, both from zero to infinity.

The HVD (half value duration), that is the residence time of nifedipine in the plasma equal to half of the peak value, was calculated with graphic method.

The results obtained from the test prove that the preparation "B" (Adalat AR) shows an average peak value of 32 ng/ml after two hours from the administration of the 20 mg dose, whilst the conventional preparation "A" (Adalat) induces a peak value of 65.4 ng/ml as soon as one hour after swallowing of a 10 mg dose. The preparation "C" (Example 1) has a maximum concentration of 40.9 ng/ml after three hours from the administration of the 20 mg dose.

12 hours after the administration of the dose, the average levels of Adalat (6 hours after the second dose) and Adalat AR, respectively fall to 9.5 and to 5.1 ng/ml, whereas the average concentration is maintained at 12.6 ng/ml due to nifedipine in Example 1. A similar observation is made for the levels of the 24th hour, corresponding for "A", "B" and "C", in order, to 0.95, 1.5 and 4.5 ng/ml (see Table 1 and Fig. 1). (λ) The K_{el} of the conventional product was calculated according to a pharmacokinetic model with two compartments for extravascular administration (triexponential equation).

The calculation of the area under the curve (AUC) gave a confirmation of the good bioavailability of the preparation "C" with respect to the two comparison forms: the preparation "A" presents an AUC of 363.5 ng/mlxh while such value for preparation "B" is equal to 261.7 ng/mlxh (72% with respect to the previous), and rises to 423.3 ng/mlxh for the preparation "C", which corresponds to 116.5% with respect to the conventional product "A" and to 162% with respect to the sustained release product "B" (see Table 2).

The evaluation of the retard characteristics, based on a comparison of the parameters MRT and HVD, indicates more satisfying results proved by preparation "C". The latter's curve maintains significant average values higher than the previous products: in fact, the average value of the MRT is, for the specification "C", equal to 9.1 hours as opposed to the 7.1 of the similar sustained release product "B". The conventional product presents a MRT of only 4.4 hours, that is, about twice as little as that of product "C".

Also the HVD is 1.4 hours for the conventional product "A", rising to 6.6 hours for the sustained release product "B" and to 7.2 hours for the sustained release product "C" in Example 1 (see Table 3). Therefore, in parity of dosage, the product "C" also combines a good retard effect with a satisfactory bioavailability, equal to over one and a half times that of the similar Adalat AR product on the market.

TABLE 1 - AVERAGE PLASMA LEVELS OF NIFEDIPINE (ng/ml)
AFTER ADMINISTRATION OF THREE PREPARATIONS

t(h)	1	2	3	4	6	7	8	9	12	14	16	24
pr.												
"A"	65.4	28.1	16.9	11.9	7.9	72.0	33.6	21.6	9.5	7.2	5.5	0.95
"B"	14.7	32.0	24.0	30.6	25.2	--	--	8.9	5.1	--	--	1.5
"C"	19.4	38.0	40.9	38.7	25.9	--	--	18.8	12.6	--	--	4.5

TABLE 2 - MAIN PHARMACOKINETIC CHARACTERISTICS
OF TEST PREPARATIONS

Preparation	C _{max} (ng/ml)	T _{max} (h)	AUC 0-∞ (ng/ml·h)	X/A ^{a)} (%)
"A"	65.4	1	363.5	---
"B"	32.0	2	261.7	72.0
"C"	40.9	3	423.3	116.5

a) relative bioavailability compared with reference product "A"

TABLE 3 - PARAMETERS ^{a)} INDICATING THE SUSTAINED RELEASE
CHARACTERISTICS OF TEST PREPARATIONS

preparation	MRT (h)	HV (ng/ml)	HVD (h)
"A"	4.4	32.7	1.4
"B"	7.1	16.0	6.6
"C"	9.1	20.5	7.2

a)
MRT = mean residence time
HV = half value
HVD = half value duration

EXAMPLE 7

The formulation in 40 mg tablets (Example 2) underwent a bioavailability test on six healthy adults of both sexes, in comparison with a sustained release product already on the market.

The experimental products were labelled as follows:

"A" = Adalat AR (Bayer), 20 mg tablets

"B" = Nifedipine of Example 2, 40 mg tablets

The product "A" was administered in two successive doses of 20 mg, the first at zero time and the second after 12 hours: the blood withdrawals were effected after 1, 2, 4, 6, 9, 12, 14, 16, 18, 22 and 24 hours from the assumption of the first dose.

Preparation "B", instead, was administered in a single dose of 40 mg, and the blood withdrawals were effected after 1, 2, 4, 6, 9, 12, 16 and 24 hours.

The obtained average curves of the plasmatic levels are reported in Table 1A and illustrated in Fig. 1.

From these, the maximum concentrations (C_{max}), the relative appearance times (T_{max}), and the areas under the concentration-time curve (AUC) from zero to infinity, were calculated. These were obtained from the total of the area comprised between zero and C_n (C_n = last concentration found) and calculated with the trapeze method, plus the portion comprised between C_n and infinity, obtained by applying the formula

5 $C_n K_{el}$, wherein K_{el} (x) is the elimination constant (= 0.185) of the conventional product.
(x) The K_{el} of the conventional product was calculated according to a two-compartment pharmacokinetic model (trixponential equation).

As an indication of the sustained release characteristics of the preparations, the following parameters were used: MRT (= mean residence time) and HVD (half value duration); MRT is the average residence
10 time of the active principle in the plasma and is calculated according to the formula:

$$MRT = \frac{AUM_{0-\infty}}{AUC_{0-\infty}}$$

15

wherein $AUM_{0-\infty}$ is the area under the first moment of the curve and $AUC_{0-\infty}$ is the conventional area under the curve, both from zero to infinity.

HVD is the residence time in the plasma of an active principle equal to half of the maximum
20 concentration: such time is calculated according to a graphic method.

Examining the results obtained from the test (see Table 1A and Fig. 1), it is noted that the delaying product "A" for comparison (Adalat AR) presents its maximum level (48.2 ng/ml) one hour after the administration of the 20 mg dose, whilst the preparation "B" (Example 2) has a maximum concentration of 62.6 ng/ml two hours after swallowing of the 40 mg dose. Its average curve decreases more slowly than that
25 of the product "A", so much so that at a distance of 24 hours after the beginning of the test, the plasmatic level is 11.4, as opposed to the 7.1 ng/ml presented by the comparison product after two administrations.

The AUC 0- ∞ calculation gives a confirmation of the good bioavailability of the preparation in Example 2 which is equal to 134% with respect to that of the comparison product (see Table 2A).

Also the retard product characteristics are in favour of the preparation "B". In fact, it has a MRT of 10.5
30 hours, whilst that calculated for product "A" is 5.6 hours; the HVD is 7 hours for Example 2 and 3.3 hours for Adalat AR. Therefore, the residence time of nifedipine in the plasma is practically doubled with the administration of the product "B" with respect to the values found after swallowing of "A" (see Table 3A).

It can be concluded, therefore, that the formulation indicated as "Example 2", in dosage parity with the comparison product but, differing from this, in a single administration, shows, with respect to it, an improved
35 bioavailability and a more satisfying retard product characteristic, which permits an efficient therapeutical application with a single daily administration.

40

45

50

55

TABLE 1A - AVERAGE PLASMA LEVELS OF NIFEDIPINE (ng/ml)
AFTER ADMINISTRATION OF THREE PREPARATIONS

t(h) pt.	1	2	4	6	9	12	14	16	18	22	24
"A"	48.2	37.2	22.6	17.2	7.3	5.4	56	31.2	17.2	7.4	7.1
"B"	46.4	62.6	50.7	39.5	24.9	20.5	--	17.3	--	--	11.4

TABLE 2A- MAIN PHARMACOKINETIC CHARACTERISTICS
OF TEST PREPARATIONS

preparation	C _{max} (ng/ml)	T _{max} (h)	AUC 0-∞ (ng/mlxh)	X/A ^{a)} (%)
"A"	48.2	1	521.3	--
=====				
"B"	62.6	2	697.9	133.9

a) relative bioavailability compared with reference product "A"

TABLE 3A PARAMETERS a) INDICATING THE SUSTAINED RELEASE
CHARACTERISTICS OF TEST PREPARATIONS

Preparation	MRT (h)	HV (ng/ml)	HVD (h)
"A"	5.6	24.1	3.3
"B"	10.5	31.3	7.0

a) MRT = mean residence time
HV = half value
HVD = half value duration

Claims

1. Solid pharmaceutical formulation consisting essentially of nifedipine as active principle, PEG, and inert excipient, characterized in that a starting solid micronized inert excipient which is soluble in the gastrointestinal juices is provided either per se or homogeneously admixed with micronized active principle, and in that polyethylene glycol of high molecular weight between about 2000 and 6000 is precipitated thereon in the case of an admixture of the starting micronized inert excipient plus micronized active principle, or in that polyethylene glycol of high molecular weight between about 2000 and 6000 together with micronized active principle is co-precipitated in the starting micronized inert excipient per se, the product being in the form of very fine particles having an extremely high total specific surface obtained by a granulation step through an INOX ASTM N°25 stainless steel wire mesh with openings of 0.71 mm, possibly after one or more pregranulation steps through a larger ASTM N°8

screen with openings of 2.38 mm to speed up to process.

2. Pharmaceutical formulation according to Claim 1, characterized in that the ratio between active principle and polyethylene glycol varies between 20:80 and 80:20 and preferably between 40:60 and 60:40.
- 5 3. Pharmaceutical formulation according to the preceding Claims, characterized in that the polyethylene glycol has a molecular weight comprised between 5000 and 6000.
4. Pharmaceutical formulation according to the preceding Claims, characterized in that the co-precipitate is obtained in one or more phases.
- 10 5. Solid pharmaceutical formulation according to the preceding Claims in the form of a sustained release tablet.
- 15 6. Pharmaceutical formulation according to the preceding Claims in the form of tablets, characterized in that there are one or more types of hydroxypropylmethylcellulose present among the excipients.
7. Pharmaceutical formulation according to the preceding Claims in the form of tablets characterized by the fact of having such a retard effect that a single daily administration can be effected.
- 20 8. A form of oral administration based on nifedipine or its derivatives containing a solid pharmaceutical formulation as specified in any one of the Claims 1 - 7.
9. Process for the preparation of a solid pharmaceutical formulation according to Claim 1, characterized by the steps of preparing a solution of nifedipine, or its derivatives, and polyethylene glycol of high molecular weight between about 2000 and 6000, in a solvent, or mixture of common solvents, and dispersing the solution on a micronized inert excipient, soluble in the gastrointestinal juices or of preparing a solution of high molecular weight polyethylene glycol and dispersing the solution into a homogeneous mixture of active substances and inert excipient, soluble in the gastrointestinal juices, both the active substance and the inert excipient being micronized, by a granulation step through an INOX ASTM N°25 stainless steel wire mesh with openings of 0.71 mm, possibly after one or more pregranulation steps through a larger ASTM N°8 screen with openings of 2.38 mm to speed up to process.
- 30 10. Process according to Claim 9, characterized in that diluted solutions, which are added in several phases, are used, grinding the granulate between one phase and another.
11. Process according to Claim 9, characterized in that the ratio between active principle and polyethylene glycol varies between 20:80 and 80:20 and preferably between 40:60 and 60:40.
- 40 12. Process according to Claim 9, characterized in that the polyethylene glycol has a molecular weight comprised between 5000 and 6000
13. Process according to Claim 9, characterized in that the micronized inert excipient is chosen from sucrose, lactose, glucose, fructose, levulose, mannitol, sorbitol, glycol, xylitol, pentaerythritol, maltodextrine.
- 45 14. Process according to Claim 13, characterized in that the ratio between the coprecipitate of polyethylene glycol and active principle and the micronized inert excipient varies preferably between 1:20 and 1:4.
- 50 15. Process according to Claim 9, characterized by the fact that substances which swell upon contact with the gastrointestinal juices and successively dissolve slowly, and which are preferably hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose, carboxyvinyl polymers, xanthan gum, in quantities varying in weight between 5% and 50% of the tablet and preferably between 10% and 30%, are added so as to obtain a prolongation of the retard effect.
- 55

Revendications

1. Formulation pharmaceutique solide comprenant essentiellement de la nifédipine en tant que composant actif, un polyéthylène glycol et un excipient inerte, caractérisée en ce qu'un excipient inerte micronisé solide de départ qui est soluble dans les sucs gastrointestinaux, est fourni soit per se soit en mélange homogène avec le composant actif micronisé, et qu'un polyéthylène glycol de haut poids moléculaire de l'ordre d'environ 2000 à 6000 est fait précipité sur le mélange éventuel de l'excipient inerte micronisé de départ et du composant actif micronisé, ou qu'un polyéthylène glycol de haut poids moléculaire de l'ordre d'environ 2000 à 6000 est, avec le composant actif micronisé, co-précipité dans l'excipient inerte micronisé de départ per se, le produit étant sous la forme de particules très fines ayant une aire spécifique totale extrêmement élevée obtenue par une étape de granulation à travers un tamis métallique en acier inoxydable INOX ASTM N°25 ayant des ouvertures de 0,71 mm, éventuellement après une ou plusieurs étapes de pré-granulation à travers un tamis plus grand ASTM N°8 ayant des ouvertures de 2,38 mm pour accélérer le procédé.
2. Formulation pharmaceutique suivant la revendication 1, caractérisée en ce que le rapport du composant actif au polyéthylène glycol varie entre 20 : 80 et 80 : 20 et de préférence entre 40 : 60 et 60 : 40.
3. Formulation pharmaceutique suivant les revendications précédentes, caractérisée en ce que le polyéthylène glycol a un poids moléculaire compris entre 5000 et 6000.
4. Formulation pharmaceutique suivant les revendications précédentes, caractérisée en ce que le co-précipité est obtenu en une ou plusieurs phases.
5. Formulation pharmaceutique suivant les revendications précédentes, caractérisée en ce qu'elle est sous forme d'un comprimé à libération continue.
6. Formulation pharmaceutique suivant les revendications précédentes sous la forme de comprimés, caractérisée en ce qu'il y a un ou plusieurs types d'hydroxypropylméthylcellulose présents parmi les excipients.
7. Formulation pharmaceutique suivant les revendications précédentes sous la forme de comprimés, caractérisée en ce que ceux-ci ont un effet retard permettant l'administration d'une prise unique quotidienne.
8. Forme d'administration orale à base de nifédipine ou de ses dérivés, caractérisée en ce qu'elle contient une formulation pharmaceutique suivant l'une quelconque des revendications 1 à 7,
9. Procédé pour préparer une formulation pharmaceutique solide suivant la revendication 1 caractérisé par les étapes de préparation d'une solution de nifédipine ou de ses dérivés et de polyéthylène glycol ayant un poids moléculaire élevé de l'ordre d'environ 2000 à 6000, dans un solvant ou un mélange de solvants courants et de dispersion de la solution sur un excipient inerte micronisé, soluble dans les sucs gastrointestinaux, ou bien de préparation d'une solution de polyéthylène glycol de haut poids moléculaire et de dispersion de la solution dans un mélange homogène de substances actives et d'excipient inerte, soluble dans les sucs gastrointestinaux, la substance active et l'excipient inerte étant tous les deux micronisés par une étape de granulation à travers un tamis métallique en acier inoxydable INOX ASTM N°25 ayant des ouvertures de 0,71 mm, éventuellement après une ou plusieurs étapes de pré-granulation à travers un tamis plus grand ASTM N°8 ayant des ouvertures de 2,38 mm pour accélérer le procédé.
10. Procédé suivant la revendication 1 caractérisé en ce qu'on utilise des solutions diluées, qui sont ajoutées en plusieurs phases, avec broyage du granulat entre une phase et une autre.
11. Procédé suivant la revendication 9, caractérisé en ce que le rapport du composant actif au polyéthylène glycol varie entre 20 : 80 et 80 : 20 et de préférence entre 40 : 60 et 60 : 40.
12. Procédé suivant la revendication 9, caractérisé en ce que le polyéthylène glycol a un poids moléculaire compris entre 5000 et 6000.
13. Procédé suivant la revendication 9, caractérisé en ce que l'excipient inerte micronisé est choisi par le

sucrose, le lactose, le glucose le fructose le lévulose, le mannitol le sorbitol, le glycolle, le xylitol, la pentaérythrite, la maltodextrine.

- 5 14. Procédé suivant la revendication 13, caractérisé en ce que le rapport entre le co-précipité de polyéthylène glycol et de composant actif et l'excipient Inerte micronisé varie de préférence entre 1 : 20 et 1 : 4.
- 10 15. Procédé suivant la revendication 9, caractérisé en ce que des substances qui gonflent au contact des sucs gastrointestinaux et ensuite se dissolvent lentement, et qui sont de préférence une hydroxypropyl-méthylcellulose, une méthylcellulose, une hydroxypropylcellulose, des polymères carboxyvinyles, une gomme xanthane, sont ajoutées en des quantités variant entre 5% et 50% en poids du comprimé et de préférence entre 10% et 30% en poids, de façon à obtenir un prolongement de l'effet retard.

Patentansprüche

- 15 1. Feste pharmazeutische Zubereitung, bestehend im wesentlichen aus Nifedipin als Wirkstoff, PEG und einem Inerten Träger, dadurch gekennzeichnet, dass ein fester, mikronisierter, inerte Träger, der in den Magendarmsäften löslich ist, als Ausgangsmaterial entweder als solcher oder homogen mit dem mikronisierten Wirkstoffprinzip vermischt bereitgestellt wird und dass Polyethylenglykol mit einem hohen Molekulargewicht zwischen etwa 2000 und 6000 im Fall eines Gemisches des mikronisierten, inerten Trägers als Ausgangsprodukt plus dem mikronisierten Wirkstoffprinzip darauf ausgefällt wird oder dass Polyethylenglykol mit einem hohen Molekulargewicht zwischen etwa 2000 und 6000 zusammen mit dem mikronisierten Wirkstoffprinzip auf dem mikronisierten, inerten Träger als Ausgangsprodukt als solchem kopräzipitiert werden, wobei das Produkt in Form von sehr feinen Teilchen mit einer äusserst hohen gesamten spezifischen Oberfläche vorliegt, die mittels einer Granulationsstufe durch ein Drahtsieb aus rostfreiem Stahl INOX ASTM Nr. 25 mit einer lichten Maschenweite von 0,71 mm, gegebenenfalls nach einer oder mehreren Vorgranulationsstufen durch ein grösseres ASTM Nr. 8-Sieb mit lichter Maschenweite von 2,38 mm zur Beschleunigung des Verfahrens, erhalten worden ist.
- 20 2. Pharmazeutische Zubereitung nach Anspruch 1, dadurch gekennzeichnet, dass das Verhältnis zwischen Wirkstoffprinzip und Polyethylenglykol zwischen 20 : 80 und 80 : 20 und vorzugsweise zwischen 40 : 60 und 60 : 40 variiert.
3. Pharmazeutische Zubereitung nach den vorstehenden Ansprüchen, dadurch gekennzeichnet, dass das Polyethylenglykol ein Molekulargewicht zwischen 5000 und 6000 aufweist.
- 35 4. Pharmazeutische Zubereitung nach den vorstehenden Ansprüchen, dadurch gekennzeichnet, dass das Copräzipitat in einer oder mehreren Phasen erhalten wird.
- 40 5. Feste pharmazeutische Zubereitung nach den vorstehenden Ansprüchen in Form einer Tablette mit verzögerter Wirkstoffabgabe.
6. Pharmazeutische Zubereitung nach den vorstehenden Ansprüchen in Form von Tabletten, dadurch gekennzeichnet, dass eine oder mehrere Typen von Hydroxypropylmethylcellulose unter den Trägern vorhanden sind.
- 45 7. Pharmazeutische Zubereitung nach den vorstehenden Ansprüchen in Form von Tabletten, dadurch gekennzeichnet, dass sie eine solche Verzögerungswirkung aufweisen, dass eine einzige tägliche Verabreichung vorgenommen werden kann.
- 50 8. Darreichungsform für die orale Verabreichung, basierend auf Nifedipin oder dessen Derivaten mit einem Gehalt an einer festen pharmazeutischen Zubereitung gemäss einem der Ansprüche 1 bis 7.
- 55 9. Verfahren zur Herstellung einer festen pharmazeutischen Zubereitung nach Anspruch 1, gekennzeichnet durch die Herstellung einer Lösung von Nifedipin oder dessen Derivaten und von Polyethylenglykol mit einem hohen Molekulargewicht zwischen etwa 2000 und 6000 in einem Lösungsmittel oder einem Gemisch aus gemeinsamen Lösungsmitteln und durch Dispergieren der Lösung an einem mikronisierten, inerten Träger, der in Magendarmsäften löslich ist, oder durch die Herstellung einer Lösung von

EP 0 220 760 B1

- hochmolekularem Polyethylenglykol und durch Dispergieren der Lösung zu einem homogenen Gemisch von Wirkstoffen und inertem Träger, der in den Magendarmsäften löslich ist, wobei sowohl der Wirkstoff als auch der inerte Träger mittels einer Granulierungsstufe durch ein Drahtsieb aus rostfreiem Stahl INOX ASTM Nr. 25 mit einer lichten Maschenweite von 0,71 mm, gegebenenfalls nach einer oder mehreren Vorgranulierungsstufen durch ein grösseres ASTM Nr. 8-Sieb mit einer lichten Maschenweite von 2,38 mm zur Beschleunigung des Verfahrens mikronisiert worden sind.
10. Verfahren nach Anspruch 9, dadurch gekennzeichnet, dass verdünnte Lösungen, die in mehreren Phasen zugesetzt werden, verwendet werden, wobei das Granulat zwischen zwei Phasen gemahlen wird.
11. Verfahren nach Anspruch 9, dadurch gekennzeichnet, dass das Verhältnis zwischen Wirkstoffprinzip und Polyethylenglykol zwischen 20 : 80 und 80 : 20 und vorzugsweise zwischen 40 : 60 und 60 : 40 variiert.
12. Verfahren nach Anspruch 9, dadurch gekennzeichnet, dass das Polyethylenglykol ein Molekulargewicht zwischen 5000 und 6000 aufweist.
13. Verfahren nach Anspruch 9, dadurch gekennzeichnet, dass der mikronisierte, inerte Träger unter Saccharose, Lactose, Glucose, Fructose, Lävulose, Mannit, Sorbit, Glykokol, Xylit, Pentaerythrit und Maltodextrin ausgewählt ist.
14. Verfahren nach Anspruch 13, dadurch gekennzeichnet, dass das Verhältnis zwischen dem Copräzipitat aus Polyethylenglykol und Wirkstoffprinzip und dem mikronisierten, inerten Träger vorzugsweise zwischen 1 : 20 und 1 : 4 variiert.
15. Verfahren nach Anspruch 9, dadurch gekennzeichnet, dass Substanzen, die bei Kontakt mit den Magendarmsäften quellen und anschliessend langsam in Lösung gehen und bei denen es sich vorzugsweise um Hydroxypropylmethylcellulose, Methylcellulose, Hydropropylcellulose, Carboxyvinylpolymere oder Xantangummi handelt, in Mengen, die zwischen 5 % und 50 % der Tablette und vorzugsweise zwischen 10 % und 30 % variieren, zugesetzt werden, um eine Verlängerung der Verzögerungswirkung zu erzielen.




FIG. 1




FIG. 2